Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Osteoporosis
•
Primary Care
How would you approach a patient with osteoporosis who remains at risk for osteoporotic fracture and who had an atypical femur fracture on denosumab?
Related Questions
What patient factors are most important when considering who needs a broader workup for osteoporosis prior to starting therapy?
How would you manage a patient with symptomatic Paget’s disease and osteoporosis who developed new fragility fractures while on Fosamax?
Are SGLT2 inhibitors contraindicated in patients with osteoporosis and history of vertebral and hip fractures?
How do you approach decision-making around initiation of osteoporosis therapy in patients with advanced dementia?
Do you start bisphosphonates after tapering off menopausal hormone therapy to prevent the rapid decline of bone mineral density?
Can you use bisphosphonates in a patient with osteoporosis who has had prior avascular necrosis of TMJ due to steroid use?
Is there a maximum duration for raloxifene use?
Would you stop romosozumab if a patient developed mild asymptomatic hypocalcemia while on treatment?
Is it safe to continue teriparatide beyond 3 years in a patient with severe osteoporosis and atypical fracture of the femur?
What degree of treatment related hypocalcemia would you tolerate with denosumab before switching agents?
